← Back to all trials
Recruiting
NCT07865377
Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation
Conditions: Coronary Artery Disease (CAD), Menopause, Hormones
Sex: Female
Ages: 45 Years – 70 Years
Healthy volunteers: No
Phase: NA
Enrollment: 80
Sponsor: InCor Heart Institute
Location: Servico de Prevencao, Cardiopatia na Mulher e Reabilitacao Cardiovascular, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, São Paulo São Paulo
Summary
Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.
Eligibility Criteria
Inclusion Criteria:
* Postmenopausal women;
* Diagnosed coronary artery disease;
* Stable coronary disease;
Exclusion Criteria:
* Hypo- or hyperthyroidism,
* Rheumatic disease,
* Use of alcohol,
* hepatic failure,
* renal failure
* hormone replacement therapy
* use of insulin
Source: ClinicalTrials.gov (NCT07865377). StuddyBuddy aggregates publicly available trial information.
